Reset filter
Trefwoorden
Cancer, Endometrial ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

78 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility Cancer NCT00756847

- 10-11-17 - 1 Formulier, 2 Itemgroepen, 20 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00756847

Eligibility Endometrial Cancer NCT01262040

- 06-12-19 - 1 Formulier, 2 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive; ODM derived from: https://clinicaltrials.gov/show/NCT01262040

Registration Endometrial Cancer NCT00063999

- 29-07-15 - 1 Formulier, 4 Itemgroepen, 27 Data-elementen, 1 Taal
Itemgroepen: HEADER MODULE, TRACKING INFORMATION, DEMOGRAPHIC INFORMATION, FOOTER MODULE
Registration Endometrial Cancer NCT00063999 Registration Form, GOG-0209, Form R Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B23EF80F-A3B1-0ED8-E034-0003BA12F5E7

Endometrial Cancer NCT00807768 On-Study - GOG-0249 Uterine Cancer - On Study Form - 2760084v1.0 - GOG-0249 Uterine Cancer - On Study Form

- 09-01-15 - 1 Formulier, 4 Itemgroepen, 26 Data-elementen, 1 Taal
Itemgroepen: HEADER MODULE, UTERINE CANCER: DISEASE DESCRIPTION, Lymph Node Metastasis, COMMENTS
GOG-0249 Uterine Cancer - On Study Form Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4FF32E53-FBDF-394B-E044-0003BA3F9857

dbGaP phs000841 Tyrosine Kinase Mutations in Endometrial Cancer - pht004420.v1.p1

- 29-01-25 - 5 Formulieren, 1 Itemgroep, 5 Data-elementen, 1 Taal
Itemgroep: pht004420
Principal Investigator: Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Endometrial Carcinomas https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000841 The purpose of the original study was to search for somatic mutations in the tyrosine kinome of serous and clear cell endometrial carcinomas (human). The study was conducted in two phases. Phase 1: A mutation discovery screen, in which ~577 exons encoding the catalytic domains of 86 tyrosine kinases were PCR-amplified and bidirectionally Sanger sequenced from 24 serous, 11 clear cell, and 5 mixed histology endometrial tumors. This was followed by alignment of sequence reads to the human reference sequence and subsequent nucleotide variant calling to identify potential somatic (tumor-specific) mutations. Potential somatic mutations were confirmed by re-amplification and sequencing of the relevant tumor DNA as well as matched non-tumor ("normal") DNA from the same case. Phase 2: A mutation prevalence screen, in which the non-catalytic regions two tyrosine kinase genes, TNK2 and DDR1, were PCR-amplified and sequenced from the 40 discovery screen tumors, and all coding exons of TNK2 and DDR1 were PCR-amplified and sequenced from another 10 clear cell, 21 serous, and 41 endometrioid endometrial tumors, in an effort to identify additional somatic mutations in each gene. Exons encoding the exonuclease domain of POLE were also sequenced to document somatic mutations.

pht004421.v1.p1

1 Itemgroep 4 Data-elementen

pht004422.v1.p1

1 Itemgroep 12 Data-elementen

Eligibility

1 Itemgroep 4 Data-elementen

pht004419.v1.p1

1 Itemgroep 3 Data-elementen

Endometrial Cancer NCT00063999 On-Study - Primary Gynecologic Cancer - On Study Form, GOG-0209, Form OSE - 2450967v1.0 - Primary Gynecologic Cancer - On Study Form, GOG-0209, Form OSE

- 09-01-15 - 1 Formulier, 3 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: HEADER MODULE, ENDOMETRIAL: DISEASE DESCRIPTION, COMMENTS
Primary Gynecologic Cancer - On Study Form, GOG-0209, Form OSE Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0CC45F2A-6926-41E8-E044-0003BA3F9857

Endometrial Cancer NCT00063999 On-Study - Recurrent Gynecologic Cancer - On Study Form, GOG-0209, Form OS-R - 2077062v3.0 - Recurrent Gynecologic Cancer - On Study Form, GOG-0209, Form OS-R

- 09-01-15 - 1 Formulier, 6 Itemgroepen, 39 Data-elementen, 1 Taal
Itemgroepen: HEADER MODULE, DISEASE DESCRIPTION - PRIOR HISTORY, DISEASE DESCRIPTION - CURRENT HISTORY, PRIOR TREATMENT FOR GYNECOLOGIC CANCER, FOOTER MODULE, CCRR MODULE
Recurrent Gynecologic Cancer - On Study Form, GOG-0209, Form OS-R Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B2400102-D1C7-0EDF-E034-0003BA12F5E7

Endometrial Cancer Radiation Therapy NCT00807768 GOG-0249 - Quality of Life

- 14-07-17 - 1 Formulier, 7 Itemgroepen, 60 Data-elementen, 1 Taal
Itemgroepen: PHYSICAL WELLBEING, FUNCTIONAL WELLBEING, Additional Concerns, FACT/GOG-NTX, FACIT Fatigue Scale, PROMIS Fatigue Short Form 1, Clinical Staff
GOG-0249 Quality of Life (QOL) Form Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Endometrial Cancer NCT00807768 Quality of Life - GOG-0249 Quality of Life (QOL) Form - 2786253v1.0

Endometrial Cancer Combination Chemotherapy NCT00063999 GOG-0209 - Quality of Life FACT-En

- 14-07-17 - 1 Formulier, 3 Itemgroepen, 34 Data-elementen, 1 Taal
Itemgroepen: Physical Well-Being, Functional Well-Being, Additional Concerns
Endometrial Cancer NCT00063999 Quality of Life - FACT-En (Version 4), GOG-0209 - 2077672v3.0 FACT-En (Version 4), GOG-0209 Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer https://clinicaltrials.gov/ct2/show/NCT00063999

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 27-11-24 - 5 Formulieren, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: IG.elig
Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 Itemgroep 5 Data-elementen

pht004835.v1.p1

1 Itemgroep 5 Data-elementen

pht004836.v1.p1

1 Itemgroep 16 Data-elementen

pht004837.v1.p1

1 Itemgroep 5 Data-elementen

On-Study - Primary Endometrial Cancer - On-Study Form - 2019340v3.0 - Primary Endometrial Cancer - On-Study Form

- 09-01-15 - 1 Formulier, 5 Itemgroepen, 29 Data-elementen, 1 Taal
Itemgroepen: CRF Header, Endometrial: Form Administration, Endometrial: Disease Description, ENDOMETRIAL: DISEASE TREATMENT AND STATUS AT ENTRY, Comments
Primary Endometrial Cancer - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=16D70DED-556D-4F42-E044-0003BA3F9857

dbGaP phs000893 Genome-Wide Association Study of Endometrial Cancer in E2C2 - pht005501.v1.p1

- 02-04-24 - 6 Formulieren, 1 Itemgroep, 3 Data-elementen, 1 Taal
Itemgroep: pht005501
Principal Investigator: Immaculata De Vivo, PhD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA and Harvard TH Chan School of Public Health, Boston, MA, USA MeSH: Carcinoma, Endometrioid,Endometrial Neoplasms,Uterine Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000893 Endometrial cancer, the most common gynecological malignancy in the United States, has both an environmental and genetic component. To this end, we conducted a genome-wide association study to identify genes involved in endometrial cancer using studies from the NCI-supported Epidemiology of Endometrial Cancer Consortium (E2C2). For the discovery stage we included samples from 6 cohort and 7 case control studies through 2007. The total number of cases genotyped were 2,307, white women of European descent, and 2,307 matched controls using the Illumina HumanOmniExpress platform. We conducted the replication using the Infinium HumanExome BeadChip, which successfully genotyped 177,139 variants in 1055 cases and 1778 controls from four ethnically diverse studies that are part of the Epidemiology of Endometrial Cancer Consortium (E2C2). The overall goal is to determine whether certain genotypes are predictive of future endometrial cancer risk, and whether the genotypes interact with established endometrial risk factors.

pht005502.v1.p1

1 Itemgroep 15 Data-elementen

pht005503.v1.p1

1 Itemgroep 8 Data-elementen

pht005504.v1.p1

1 Itemgroep 4 Data-elementen

Eligibility

1 Itemgroep 2 Data-elementen

pht005500.v1.p1

1 Itemgroep 4 Data-elementen

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial